Abstract
Managing patients with severe asthma during the coronavirus pandemic and COVID-19 is a challenge. Authorities and physicians are still learning how COVID-19 affects people with underlying diseases, and severe asthma is not an exception. Unless relevant data emerge that change our understanding of the relative safety of medications indicated in patients with asthma during this pandemic, clinicians must follow the recommendations of current evidence-based guidelines for preventing loss of control and exacerbations. Also, with the absence of data that would indicate any potential harm, current advice is to continue the administration of biological therapies during the COVID-19 pandemic in patients with asthma for whom such therapies are clearly indicated and have been effective. For patients with severe asthma infected by SARS-CoV-2, the decision to maintain or postpone biological therapy until the patient recovers should be a case-by-case based decision supported by a multidisciplinary team. A registry of cases of COVID-19 in patients with severe asthma, including those treated with biologics, will help to address a clinical challenge in which we have more questions than answers.
【저자키워드】 severe acute respiratory syndrome coronavirus 2, Coronavirus disease 2019, Randomized controlled trials, monoclonal antibody, intensive care unit, lung, angiotensin-converting enzyme 2, inhaled corticosteroids, interleukin 6, Food and Drug Administration, adverse events, United States of America, antibody-dependent cell-mediated cytotoxicity, British Thoracic Society, COVID-19coronavirus disease 2019, SARS-CoV-2severe acute respiratory syndrome coronavirus 2, ICUIntensive Care Unit, FDAFood and Drug Administration, RCTsrandomized controlled trials, ACE2angiotensin-converting enzyme 2, AAAAIAmerican Academy of Allergy, Asthma and Immunology, American Academy of Allergy, ACAAIAmerican College of Allergy, American College of Allergy, ADCCAntibody-Dependent Cell-mediated Cytotoxicity, AEsAdverse events, BTSBritish Thoracic Society, DNADeoxyribonucleic acid, Deoxyribonucleic acid, ERSEuropean Respiratory Society, European Respiratory Society, ELFEuropean Lung Foundation, European Lung Foundation, IgEImmunoglobulin E, Immunoglobulin E, IL4Interleukin 4, Interleukin 4, IL5Interleukin 5, Interleukin 5, IL5RaInterleukin 5 alfa receptor, Interleukin 5 alfa receptor, IL5rInterleukin 5 receptor, Interleukin 5 receptor, IL6Interleukin 6, IL13Interleukin 13, Interleukin 13, ICSinhaled corticosteroids, EBMEvidence Based Medicine, Evidence Based Medicine, GINAGlobal Initiative for Asthma, Global Initiative for Asthma, GSKGlaxo Smith Kline, Glaxo Smith Kline, mAbMonoclonal antibody, NHLBINational Heart, and Blood Institute, National Heart, OCSOral corticosteroids, Oral corticosteroids, PDGFRAPlatelet-Derived Growth Factor Receptor A, Platelet-Derived Growth Factor Receptor A, PROSE studyPreventative Omalizumab or Step-up therapy for fall Exacerbations study, Preventative Omalizumab or Step-up therapy for fall Exacerbations study, SAEsSerious Adverse Events, Serious Adverse Events, SARPSevere Asthma Research Programme, Severe Asthma Research Programme, SCSubcutaneous, Subcutaneous, SIAAICItalian Society of Allergy, Asthma and Clinical Immunology, Italian Society of Allergy, T2Type 2 inflammation, Type 2 inflammation, TMPRSS2Transmembrane Protease Serine 2 Enzyme, Transmembrane Protease Serine 2 Enzyme, USAUnited States of America, 【초록키워드】 COVID-19, SARS-CoV-2, Asthma, coronavirus, pandemic, therapy, COVID-19 pandemic, Patient, medication, underlying diseases, administration, clinician, help, physician, authority, Affect, recommendation, effective, managing, indicated, the patient, supported, treated, question, absence, maintain, COVID-19 in patient, 【제목키워드】 COVID-19, Asthma,